Acendis Healthcare Gmbh company information, Employees & Contact Information

Ascendis Pharma submits EU application for achondroplasia treatment Investing.com

Ascendis Submits Marketing Authorisation Application to the GlobeNewswire

Ascendis Pharma (ASND) Seeks EU Approval for Achondroplasia Trea GuruFocus

MAA Submission to EMA: Ascendis Seeks EU Approval for TransCon CNP to Treat Achondroplasia Stock Titan

Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory (ASND) Seeking Alpha

Ascendis submits application to market TransCon CNP in EU MSN

Ascendis: After Long Bull Run, New Commercial Challenges Suggest Rating Downgrade (ASND) Seeking Alpha

Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia GlobeNewswire

BioMarin Takes Legal Action Against Ascendis Over CNP Patent in European Court Stock Titan

Ascendis Pharma Reports Second Quarter 2025 Financial Results Yahoo Finance

Ascendis Pharma Lands Long-Awaited FDA Drug Approval in Rare Hormone Deficiency MedCity News

Ascendis scores hard-fought FDA nod for hormone replacement therapy Yorvipath Fierce Pharma

Ascendis Skids as FDA Detects Death in Patient Formerly on Yorvipath BioSpace

FDA approves Ascendis drug for rare endocrine condition BioPharma Dive

Er-Kim extends agreement for Ascendis’ therapies in Eurasia Pharmaceutical Technology

Ascendis Pharma's SKYTROFA Surges 84% in Volume, Driving €364M Revenue for 2024 Stock Titan

Er-Kim Extends Exclusive Distribution Agreement with GlobeNewswire

Ascendis Pharma A/S (NASDAQ:ASND): Is Breakeven Near? Yahoo Finance

Ascendis Readies BioMarin Challenge in Achondroplasia While Others Search for Root Cause BioSpace

Ascendis Pharma Reports First Quarter 2025 Financial Results GlobeNewswire

Novo pens $285M biobucks deal to use Ascendis' tech to create monthly GLP-1 agonist Fierce Biotech

BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish Yahoo Finance

FDA turns back Ascendis' hormone drug over manufacturing issues Fierce Pharma

Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference GlobeNewswire

Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results GlobeNewswire

Ascendis' dwarfism drug accelerates growth in phase 3, teeing up challenge to BioMarin Fierce Biotech

Ascendis sells Japanese rights to Skytrofa and two other hormone drugs for $70M upfront Fierce Biotech

Sale of royalties marks new approach to funding for Ascendis medwatch.com

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025 GlobeNewswire

Another delay for Ascendis' hormone therapy as FDA extends review by 3 months Fierce Pharma

Ascendis seeks European approval for dwarfism drug medwatch.com

Ascendis’ parathyroid hormone replacement therapy wins European approval Pharmaceutical Technology

Biotech Leader Ascendis Pharma Set for Key Presentation at 2025 Wells Fargo Healthcare Conference Stock Titan

Ascendis to investigate new indications following EU approval medwatch.com

Ascendis Challenges BioMarin, But Market Response Seems Excessive (NASDAQ:BMRN) Seeking Alpha

Ascendis Consulting Accelerates Growth with Pencilz Labs Merger PRWeb

FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency GlobeNewswire

Ascendis Pharma: Yorvipath Approved, Launch Delayed, Many Other Updates Coming Up Seeking Alpha

Pfizer gets EU approval for long-acting human growth hormone, softening blow of FDA rejection Fierce Pharma

Ascendis crosses FDA finish line with once-weekly growth hormone—but Pfizer is hot on its trail Fierce Pharma

Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment Pharmafile

Ascendis Pharma's growth hormone formally approved in the EU medwatch.com

Ascendis Pharma submits drug candidate for European market approval medwatch.com

Russian billionaire to acquire South African drugmaker Ascendis Health assets The Pharma Letter

Ascendis continued big investments into 2021, driving operating deficit up medwatch.com

Ascendis CFO sells shares worth DKK millions medwatch.com

Ascendis Pharma A/S Announces Multiple TransCon Growth Hormone Presentations at the European Society of Paediatric Endocrinology Annual Meeting PR Newswire

Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in Canada PR Newswire Canada

Ascendis acquires stake in foreign languages training firm business-review.eu

Ascendis on R7. 3bn prowl in Europe IOL

Ascendis spends up to €65m in Europe IOL